

Direct metallation of thienopyrimidines using a mixed lithium-cadmium base and antitumor activity of functionalized derivatives

Katia Snégaroff,^a Frédéric Lassagne,^a Ghenia Bentabed-Ababsa,^{a,b} Ekhlass Nassar,^c Sidaty Cheikh Sid Ely,^a Stéphanie Hesse,^d Enrico Perspicace,^d Aïcha Derdour^b and Florence Mongin^{*a}

^a Chimie et Photonique Moléculaires, UMR 6510 CNRS, Université de Rennes 1, Bâtiment 10A, Case 1003, Campus Scientifique de Beaulieu, 35042 Rennes, France

^b Laboratoire de Synthèse Organique Appliquée, Faculté des Sciences de l'Université, BP 1524 Es-Senia, Oran 31000, Algérie

^c Department of Chemistry, Faculty of Women for Arts, Science and Education, Ain Shams University, Asma Fahmy Street, Heleopolis (El-Margany), Cairo, Egypt

^d Laboratoire d'Ingénierie Moléculaire et Biochimie Pharmacologique, Institut Jean Barriol, FR CNRS 2843, Université Paul Verlaine-Metz, 1 Boulevard Arago, 57070 Metz Technopôle, France


florence.mongin@univ-rennes1.fr

X-ray diffraction analysis	p. 1
NMR data	p. 2
Copies of NMR spectra	p. 5


X-ray diffraction analysis

The sample was studied with graphite monochromatized $\text{MoK}\alpha$ radiation ($\lambda = 0.71073 \text{ \AA}$). X-ray diffraction data were collected at $T = 100(2) \text{ K}$ using APEXII Bruker-AXS diffractometer. The structure was solved by direct methods using the SIR97 program,¹ and then refined with full-matrix least-square methods based on F^2 (SHELX-97)² with the aid of the WINGX program.³ All non-hydrogen atoms were refined with anisotropic thermal parameters. H atoms were finally included in their calculated positions. Except N-linked hydrogen that was introduced in the structural model through Fourier difference maps analysis, H atoms were finally included in their calculated positions. The molecular diagram was generated by ORTEP-3 (version 1.08).⁴

ORTEP figure



10a



Crystal data

10a: $\text{C}_{12}\text{H}_6\text{ClIN}_2\text{S}$; $M_r = 372.60$; $T = 100(2) \text{ K}$; $\lambda = 0.71073 \text{ \AA}$; orthorhombic; space group $P c a b$, $a = 5.8116(2) \text{ \AA}$, $b = 16.7820(6) \text{ \AA}$, $c = 24.6525(9) \text{ \AA}$, $V = 2404.36(15) \text{ \AA}^3$; $Z = 8$; $D_c = 2.059 \text{ g cm}^{-3}$; $\mu = 3.035 \text{ mm}^{-1}$; $F(000) = 1424$; crystal size = $0.22 \times 0.08 \times 0.06 \text{ mm}$; θ range for data collection: $3.52\text{--}27.46^\circ$, limiting indices: $-7 \leq h \leq 7$, $-21 \leq k \leq 19$, $-31 \leq l \leq 30$; 27353 reflections collected; 2743 reflections unique ($R_{\text{int}} = 0.0587$); $R_1(I > 2\sigma(I)) = 0.0252$; $wR_2(I > 2\sigma(I)) = 0.0495$; Crystallographic data were deposited in CSD under CCDC registration number 729714.

¹ A. Altomare, M. C. Burla, M. Camalli, G. Cascarano, C. Giacovazzo, A. Guagliardi, A. G. G. Moliterni, G. Polidori, R. Spagna, *J. Appl. Crystallogr.*, 1999, **32**, 115.

² SHELX97, release 97-2 (Programs for Crystal Structure Analysis). G. M. Sheldrick, Institut für Anorganische Chemie der Universität, Tammanstrasse 4, D-3400 Göttingen, Germany, 1998.

³ L. J. Farrugia, *J. Appl. Crystallogr.*, 1999, **32**, 837.

⁴ L. J. Farrugia, *J. Appl. Crystallogr.*, 1997, **30**, 565.

NMR data

Methyl 3-benzoylaminothiophene-2-carboxylate. ^1H NMR (CDCl_3 , 300 MHz): δ 3.88 (s, 3H), 7.51 (m, 4H), 7.99 (m, 2H), 8.27 (d, 1H, J = 5.4 Hz), 11.1 (s, 1H); ^{13}C NMR (CDCl_3 , 75 MHz): δ 52.1, 110.4, 122.3, 127.4, 128.9, 131.9, 132.3, 133.6, 145.2, 164.1, 165.2.

2-Phenyl-3*H*-thieno[3,2-*d*]pyrimidin-4-one. ^1H NMR ($(\text{CD}_3)_2\text{SO}$, 300 MHz): δ 7.48 (d, 1H, J = 5.2 Hz), 7.57 (m, 3H), 8.13 (m, 2H), 8.22 (d, 1H, J = 5.2 Hz), 12.7 (br s, 1H); ^{13}C NMR ($(\text{CD}_3)_2\text{SO}$, 75 MHz): δ 121.2, 125.4, 127.8, 128.6, 131.3, 132.5, 135.4, 154.3, 157.9, 158.5.

4-Chloro-2-phenylthieno[3,2-*d*]pyrimidine (2). ^1H NMR (CDCl_3 , 300 MHz): δ 7.51 (m, 3H), 7.62 (d, 1H, J = 5.5 Hz), 8.02 (d, 1H, J = 5.2 Hz), 8.52 (m, 2H); ^{13}C NMR (CDCl_3 , 75 MHz): δ 125.2, 128.3, 128.5, 128.7, 130.9, 136.7, 136.8, 154.9, 161.7, 162.8.

4-Chloro-2-phenylthieno[2,3-*d*]pyrimidine (3). ^1H NMR (CDCl_3 , 300 MHz): δ 7.42 (d, 1H, J = 6.0 Hz), 7.50 (m, 3H), 7.54 (d, 1H, J = 6.0 Hz), 8.52 (m, 2H); ^{13}C NMR (CDCl_3 , 75 MHz): δ 119.9, 127.4, 127.5, 128.6, 128.7, 131.1, 136.3, 155.1, 160.0, 169.7.

4-Methoxythieno[2,3-*d*]pyrimidine (4). ^1H NMR (CDCl_3 , 300 MHz): δ 4.12 (s, 3H), 7.35 (d, 1H, J = 6.0 Hz), 7.37 (d, 1H, J = 6.0 Hz), 8.64 (s, 1H); ^{13}C NMR (CDCl_3 , 75 MHz): δ 54.1, 118.6, 119.2, 124.8, 153.4, 164.3, 168.5.

4-Methoxy-2-phenylthieno[2,3-*d*]pyrimidine (6). ^1H NMR (CDCl_3 , 300 MHz): δ 4.22 (s, 3H), 7.31 (d, 1H, J = 6.0 Hz), 7.35 (d, 1H, J = 6.0 Hz), 7.50 (m, 3H), 8.55 (m, 2H); ^{13}C NMR (CDCl_3 , 75 MHz): δ 53.6, 117.1, 118.5, 124.1, 128.3, 128.4, 130.3, 137.5, 159.7, 163.8, 169.4.

4-(Pyrazol-1-yl)thieno[2,3-*d*]pyrimidine (5). ^1H NMR (CDCl_3 , 300 MHz): δ 7.26 (s, 1H), 8.26 (d, 1H, J = 6.0 Hz), 8.59 (s, 1H), 9.15 (d, 1H, J = 6.0 Hz), 9.50 (d, 1H, J = 2.7 Hz), 9.57 (s, 1H); ^{13}C NMR (CDCl_3 , 75 MHz): δ 108.7, 119.2, 123.4, 126.4, 129.0, 144.3, 151.0, 152.4, 171.7.

4-(Morpholin-4-yl)-2-phenylthieno[2,3-*d*]pyrimidine (7). ^1H NMR (CDCl_3 , 300 MHz): δ 3.88 (m, 4H), 3.97 (m, 4H), 7.24 (d, 1H, J = 6.0 Hz), 7.31 (d, 1H, J = 6.0 Hz), 7.45-7.48 (m, 3H), 8.46 (m, 2H); ^{13}C NMR (CDCl_3 , 75 MHz): δ 47.3, 66.7, 114.9, 120.2, 121.9, 128.2, 128.3, 130.1, 138.0, 158.7, 158.8, 170.7.

4-Chloro-6-iodothieno[2,3-*d*]pyrimidine (8). ^1H NMR (CDCl_3 , 300 MHz): δ 7.70 (s, 1H), 7.80 (s, 1H); ^{13}C NMR (CDCl_3 , 75 MHz): δ 82.2, 129.4, 131.3, 152.7, 152.8, 172.8.

6-Iodo-4-methoxythieno[2,3-*d*]pyrimidine (9). ^1H NMR (CDCl_3 , 300 MHz): δ 4.10 (s, 3H), 7.60 (s, 1H), 8.56 (s, 1H); ^{13}C NMR (CDCl_3 , 75 MHz): δ 54.4, 77.2, 121.1, 128.5, 153.5, 162.4, 172.5.

4-Chloro-6-iodo-2-phenylthieno[3,2-*d*]pyrimidine (10a). ¹H NMR (CDCl₃, 300 MHz): δ 7.49 (m, 3H), 7.83 (s, 1H), 8.47 (m, 2H); ¹³C NMR (CDCl₃, 75 MHz): δ 92.2, 128.5, 128.7, 131.1, 133.3, 134.9, 136.3, 152.6, 162.0, 163.0.

4-Chloro-6-iodo-2-phenylthieno[2,3-*d*]pyrimidine (11). ¹H NMR (CDCl₃, 300 MHz): δ 7.50 (m, 3H), 7.68 (s, 1H), 8.48 (m, 2H); ¹³C NMR (CDCl₃, 75 MHz): δ 80.9, 128.6, 128.7, 129.2, 129.5, 131.3, 135.9, 152.8, 159.9, 173.5.

4-Chloro-6,7-diiodo-2-phenylthieno[3,2-*d*]pyrimidine (10b). ¹H NMR (CDCl₃, 300 MHz): δ 7.48 (m, 3H), 8.54 (m, 2H); ¹³C NMR (CDCl₃, 75 MHz): δ 98.7, 101.3, 128.7, 128.8, 131.4, 132.8, 135.9, 153.1, 162.0, 162.7.

6-Iodo-4-methoxy-2-phenylthieno[2,3-*d*]pyrimidine (12). ¹H NMR (CDCl₃, 300 MHz): δ 4.21 (s, 3H), 7.48 (m, 3H), 7.60 (s, 1H), 8.49 (m, 2H); ¹³C NMR (CDCl₃, 75 MHz): δ 53.9, 76.1, 119.0, 128.4, 128.4, 128.5, 130.6, 137.2, 159.7, 162.1, 173.3.

6-Iodo-4-(morpholin-4-yl)-2-phenylthieno[2,3-*d*]pyrimidine (13). ¹H NMR (CDCl₃, 300 MHz): δ 3.89 (t, 4H, J = 4.5 Hz), 4.00 (t, 4H, J = 4.3 Hz), 7.48 (m, 3H), 7.55 (s, 1H), 8.44 (m, 2H); ¹³C NMR (CDCl₃, 75 MHz): δ 46.5, 65.9, 76.1, 116.2, 127.7, 128.4, 130.3, 130.6, 137.0, 156.3, 157.3, 173.4.

4-(Morpholin-4-yl)-2-phenyl-6-(pyridin-2-yl)-thieno[2,3-*d*]pyrimidine (14). ¹H NMR (CDCl₃, 300 MHz): δ 3.93 (m, 4H), 4.06 (m, 4H), 7.23 (ddd, 1H, J = 2.0, 4.9 and 6.0 Hz), 7.48 (m, 3H), 7.73 (m, 2H), 7.88 (s, 1H), 8.47 (m, 2H), 8.64 (dt, 1H, J = 1.2 and 4.6 Hz); ¹³C NMR (CDCl₃, 75 MHz): δ 47.3, 66.8, 116.2, 117.5, 119.6, 122.7, 128.3, 128.3, 130.2, 136.8, 138.0, 139.3, 149.8, 151.8, 158.7, 159.3, 171.2.

(S)-3-Phenyl-2-(2-phenylthieno[3,2-*d*]pyrimidin-4-ylamino)propanoic acid (15). ¹H NMR ((CD₃)₂SO, 300 MHz): δ 3.34 (AB part of an ABX system, 2H, J_{AX} = 3.7 Hz, J_{BX} = 8.9 Hz and J_{AB} = 13.6 Hz), 4.99 (m, 1H), 7.06 (t, 1H, J = 7.0 Hz), 7.15 (t, 2H, J = 7.2 Hz), 7.29 (d, 2H, J = 7.2 Hz), 7.44 (m, 4H), 7.76 (br s, 1H), 8.06 (d, 1H, J = 5.3 Hz), 8.39 (m, 2H); ¹³C NMR ((CD₃)₂SO, 75 MHz): δ 37.0, 56.3, 113.4, 124.6, 125.8, 127.7, 127.8, 128.1, 129.2, 129.7, 132.9, 138.4, 139.1, 156.5, 159.5, 160.2, 173.7.

(S)-2-(6-Iodo-2-phenylthieno[3,2-*d*]pyrimidin-4-ylamino)-3-phenylpropanoic acid (16). ¹H NMR ((CD₃)₂SO, 300 MHz): δ 3.26 (AB part of an ABX system, 2H, J_{AX} = 4.0 Hz, J_{BX} = 9.9 Hz and J_{AB} = 13.6 Hz), 4.90 (m, 1H), 7.10 (t, 1H, J = 7.2 Hz), 7.18 (t, 2H, J = 7.3 Hz), 7.31 (d, 2H, J = 7.2 Hz), 7.43 (m, 3H), 7.71 (s, 1H), 8.10 (br s, 1H), 8.33 (m, 2H); ¹³C NMR ((CD₃)₂SO, 75 MHz): δ 36.7, 56.3, 89.3, 118.3, 126.0, 127.7, 128.0, 128.2, 129.1, 129.9, 133.9, 137.9, 138.8, 155.0, 159.7, 160.9, 174.4.

(S)-2-(6,7-Diiodo-2-phenylthieno[3,2-*d*]pyrimidin-4-ylamino)-3-phenylpropanoic acid (17). ¹H NMR ((CD₃)₂SO, 300 MHz): δ 3.20 (m, 2H), 4.85 (m, 1H), 7.07 (t, 1H, J = 7.2 Hz), 7.15 (t, 2H, J = 7.3

Hz), 7.26 (br d, 2H, $J = 7$ Hz), 7.47 (m, 3H), 7.96 (br s, 1H), 8.40 (m, 2H); ^{13}C NMR ($(\text{CD}_3)_2\text{SO}$, 75 MHz): δ 36.7, 56.3, 99.9, 103.7, 125.8, 127.8, 127.9, 128.2, 129.1, 129.4, 130.2, 137.7, 139.1, 159.6, 160.6, 173.9.

(S)-3-Phenyl-2-(2-phenylthieno[2,3-*d*]pyrimidin-4-ylamino)propanoic acid (18). ^1H NMR ($(\text{CD}_3)_2\text{SO}$, 300 MHz): δ 3.29 (AB part of an ABX system, 2H, $J_{\text{AX}} = 3.8$ Hz, $J_{\text{BX}} = 10$ Hz and $J_{\text{AB}} = 13.4$ Hz), 3.71 (br s, 1H), 5.00 (m, 1H), 7.08 (t, 1H, $J = 7.1$ Hz), 7.17 (t, 2H, $J = 7.3$ Hz), 7.33 (d, 2H, $J = 7.3$ Hz), 7.43 (m, 3H), 7.49 (d, 1H, $J = 5.9$ Hz), 7.71 (d, 1H, $J = 5.9$ Hz), 8.17 (d, 1H, $J = 7.0$ Hz), 8.36 (m, 2H); ^{13}C NMR ($(\text{CD}_3)_2\text{SO}$, 75 MHz): δ 37.1, 56.3, 114.8, 119.7, 122.3, 125.9, 127.7, 127.9, 128.2, 129.1, 129.9, 137.9, 139.0, 156.5, 158.5, 166.7.

(S)-2-(6-Iodo-2-phenylthieno[2,3-*d*]pyrimidin-4-ylamino)-3-phenylpropanoic acid (19). ^1H NMR ($(\text{CD}_3)_2\text{SO}$, 300 MHz): δ 3.23 (AB part of an ABX system, 2H, $J_{\text{AX}} = 4.5$ Hz, $J_{\text{BX}} = 10.3$ Hz and $J_{\text{AB}} = 13.7$ Hz), 4.92 (m, 1H), 7.13 (t, 1H, $J = 7.2$ Hz), 7.23 (t, 2H, $J = 7.3$ Hz), 7.35 (br d, 2H, $J = 7.1$ Hz), 7.43 (m, 3H), 8.06 (s, 1H), 8.30 (m, 3H); ^{13}C NMR ($(\text{CD}_3)_2\text{SO}$, 75 MHz): δ 36.6, 55.9, 75.8, 116.7, 126.2, 127.8, 128.1, 128.3, 129.0, 129.1, 130.2, 137.4, 138.4, 154.9, 158.5, 170.7, 173.8.

(S)-2-[(6-Iodo-2-phenylthieno[2,3-*d*]pyrimidin-4-yl)(methyl)amino]-3-phenylpropanoic acid (20). ^1H NMR (CDCl_3 , 300 MHz): δ 3.12 (s, 3H), 3.40 (AB part of an ABX system, 2H, $J_{\text{AX}} = 4.4$ Hz, $J_{\text{BX}} = 9.9$ Hz and $J_{\text{AB}} = 14$ Hz), 5.11 (br s, 1H), 7.14 (m, 5H), 7.39 (m, 4H), 8.28 (br d, 2H); ^{13}C NMR (CDCl_3 , 75 MHz): δ 29.7, 34.6, 73.2, 116.6, 126.8, 128.2, 128.4, 128.6, 128.9, 130.4, 130.7, 136.9, 137.0, 137.4, 156.0, 158.1, 174.5.

(S)-2-(6-Iodo-2-phenylthieno[2,3-*d*]pyrimidin-4-ylamino)-3-phenylpropan-1-ol (21). ^1H NMR ($(\text{CD}_3)_2\text{SO}$, 300 MHz): δ 2.98 (AB part of an ABX system, 2H, $J_{\text{AX}} = 5.4$ Hz, $J_{\text{BX}} = 8.5$ Hz and $J_{\text{AB}} = 13.7$ Hz), 3.60 (m, 2H), 4.66 (m, 1H), 4.93 (t, 1H, $J = 5.6$ Hz), 7.11 (tt, 1H, $J = 7.2$ Hz and 1.3 Hz), 7.23 (t, 2H, 7.4 Hz), 7.32 (m, 2H), 7.47 (m, 3H), 7.77 (d, 1H, $J = 8.1$ Hz), 8.07 (s, 1H), 8.33 (m, 2H); ^{13}C NMR ($(\text{CD}_3)_2\text{SO}$, 75 MHz): δ 36.6, 54.0, 62.2, 75.0, 116.7, 125.9, 127.7, 127.8, 128.1, 128.3, 128.7, 129.1, 129.3, 130.1, 130.8, 131.7, 137.7, 139.3, 155.1, 158.7, 170.5.

(S)-1-(6-Iodo-2-phenylthieno[2,3-*d*]pyrimidin-4-yl)pyrrolidine-2-carboxylic acid (22). ^1H NMR ($(\text{CD}_3)_2\text{SO}$, 300 MHz): δ 1.86-2.27 (m, 4H), 3.95 (m, 2H), 4.69 (m, 1H), 7.41 (m, 3H), 7.80 (s, 1H), 8.31 (m, 2H); ^{13}C NMR ($(\text{CD}_3)_2\text{SO}$, 75 MHz): δ 21.1, 24.7, 24.8, 28.4, 31.1, 49.3, 61.5, 63.1, 74.7, 116.0, 127.8, 128.3, 130.3, 130.6, 137.2, 157.6, 174.0.

Copies of NMR spectra

